Cyclic tachyplesin I kills proliferative, non-proliferative and drug-resistant melanoma cells without inducing resistance

• Main Authors: Aurélie H. Benfield (Author), Felicitas Vernen (Author), Reuben S.E. Young (Author), Ferran Nadal-Bufí (Author), Henry Lamb (Author), Heinz Hammerlindl (Author), David J. Craik (Author), Helmut Schaider (Author), Nicole Lawrence (Author), Stephen J. Blanksby (Author), Sónia Troeira Henriques (Author)
• Format: Book
• Published: Elsevier, 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Acquired drug resistance is the major cause for disease recurrence in cancer patients, and this is particularly true for patients with metastatic melanoma that carry a BRAF V600E mutation. To address this problem, we investigated cyclic membrane-active peptides as an alternative therapeutic modality...